Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3580MR)

This product GTTS-WQ3580MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3580MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7693MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ14405MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ2679MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ8242MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ5628MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ2529MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ8150MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ1596MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW